Related Experiment Video

Updated: Aug 13, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course

Chiara Corengia1, Stefania Galimberti, Giorgio Bovo

  • 1Unit of Clinical Medicine, Department of Clinical Medicine, Prevention and Biotechnologies, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.

American Journal of Clinical Pathology
|January 19, 2006
PubMed

Insights

Hepatic iron accumulation in chronic hepatitis C (CH-C) patients is linked to HFE gene mutations and increased iron absorption. This iron buildup, especially in hepatocytes, correlates with liver damage, fibrosis, and cirrhosis.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Genetics

Background:

  • Chronic hepatitis C (CH-C) infection can lead to hepatic iron accumulation.
  • The role of HFE gene mutations in iron deposition and liver damage in CH-C is not fully understood.

Purpose of the Study:

  • To describe histopathologic features of hepatic iron in CH-C patients.
  • To investigate the relationship between HFE mutations, iron location, and hepatic damage.
  • To explore factors influencing iron distribution and liver injury.

Main Methods:

  • Histopathologic examination of liver biopsies from 206 CH-C patients.
  • Assessment of hepatic iron accumulation (hemosiderin deposits) and distribution.
  • Analysis of HFE gene mutations and correlation with iron scores and liver damage.

Main Results:

  • 90.1% of patients with iron deposits showed accumulation in hepatocytes.
  • Hepatic iron scores increased with involvement of sinusoidal and portal compartments and with HFE genotypes.
  • Severe fibrosis and cirrhosis were associated with iron in all three compartments, HFE mutations, and alcohol intake.

Conclusions:

  • Hepatic iron accumulation in CH-C may stem from increased iron absorption and release.
  • Iron amount and distribution are related to liver damage.
  • HFE mutations exacerbate iron accumulation and liver damage, but other factors are also involved.

More Related Videos

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...